Show simple item record

dc.contributor.authorMathew, G
dc.contributor.authorHannan, A
dc.contributor.authorHertzler-Schaefer, K
dc.contributor.authorWang, F
dc.contributor.authorFeng, G-S
dc.contributor.authorZhong, J
dc.contributor.authorZhao, JJ
dc.contributor.authorDownward, J
dc.contributor.authorZhang, X
dc.date.accessioned2017-11-06T09:30:52Z
dc.date.issued2016-11
dc.identifier.citationProceedings of the National Academy of Sciences of the United States of America, 2016, 113 (46), pp. 13156 - 13161
dc.identifier.issn0027-8424
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/898
dc.identifier.eissn1091-6490
dc.identifier.doi10.1073/pnas.1604450113
dc.description.abstractDeficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified an autocrine FGF signaling induced by loss of Pten in keratinocytes. In this study, we demonstrate that skin hyperplasia requires FGF receptor adaptor protein Frs2α and tyrosine phosphatase Shp2, two upstream regulators of Ras signaling. Although the PI3-kinase regulatory subunits p85α and p85β are dispensable, the PI3-kinase catalytic subunit p110α requires interaction with Ras to promote hyperplasia in Pten-deficient skin, thus demonstrating an important cross-talk between Ras and PI3K pathways. Furthermore, genetic and pharmacological inhibition of Ras-MAPK pathway impeded epidermal hyperplasia in Pten animals. These results reveal a positive feedback loop connecting Pten and Ras pathways and suggest that FGF-activated Ras-MAPK pathway is an effective therapeutic target for preventing skin tumor induced by aberrant Pten signaling.
dc.formatPrint-Electronic
dc.format.extent13156 - 13161
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectCells, Cultured
dc.subjectKeratinocytes
dc.subjectSkin
dc.subjectAnimals
dc.subjectMice, Transgenic
dc.subjectSkin Neoplasms
dc.subjectras Proteins
dc.subjectMitogen-Activated Protein Kinases
dc.subjectFibroblast Growth Factors
dc.subjectMembrane Proteins
dc.subjectSignal Transduction
dc.subjectPTEN Phosphohydrolase
dc.subjectProtein Tyrosine Phosphatase, Non-Receptor Type 11
dc.titleTargeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.
dc.typeJournal Article
rioxxterms.versionofrecord10.1073/pnas.1604450113
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfProceedings of the National Academy of Sciences of the United States of America
pubs.issue46
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Lung Cancer Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Lung Cancer Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Lung Cancer Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Lung Cancer Group
pubs.publication-statusPublished
pubs.volume113
pubs.embargo.termsNo embargo
icr.researchteamLung Cancer Groupen_US
dc.contributor.icrauthorDownward, Julian David Harry


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record